Abstract
A new series of semisynthetic, water-soluble pneumocandin analogs has been found to be extremely potent against Pneumocystis carinii in an immunocompromised-rat model. These compounds are 5 to 10 times more potent than the parent natural product, pneumocandin B0 (L-688,786) (R. E. Schwartz et al., J. Antibiot. 45:1853-1866, 1992), and > 100 times more potent than cilofungin. One compound in particular, L-733,560, had a 90% effective dose against P. carinii cysts of 0.01 mg/kg of body weight when delivered parenterally (subcutaneously, twice daily for 4 days). This compound was also effective when given orally for the treatment and prevention of P. carinii pneumonia. For treating acute P. carinii pneumonia, oral doses of 2.2 mg/kg twice daily for 4 days were required to eliminate 90% of the cysts. A once-daily oral prophylactic dose of 2.2 mg/kg prevented cyst development, and a dose of 6.2 mg/kg prevented any development of P. carinii organisms (cysts and trophozoites), as determined through the use of a P. carinii-specific DNA probe (P. A. Liberator et al., J. Clin. Microbiol. 30:2968-2974, 1992). These results demonstrate that the antipneumocystis activities of the pneumocandins can be significantly improved through synthetic modification. Several of these compounds are also extremely effective against candidiasis (K. Bartizal et al., Antimicrob. Agents Chemother. 39:1070-1076, 1995) and aspergillosis (G. K. Abruzzo et al., Antimicrob. Agents Chemother. 39:860-894, 1995) in murine models, making them attractive as broad-spectrum antifungal agents.
Full Text
The Full Text of this article is available as a PDF (257.0 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Balkovec J. M., Black R. M., Hammond M. L., Heck J. V., Zambias R. A., Abruzzo G., Bartizal K., Kropp H., Trainor C., Schwartz R. E. Synthesis, stability, and biological evaluation of water-soluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP). J Med Chem. 1992 Jan;35(1):194–198. doi: 10.1021/jm00079a027. [DOI] [PubMed] [Google Scholar]
- Bartizal K., Abruzzo G., Trainor C., Krupa D., Nollstadt K., Schmatz D., Schwartz R., Hammond M., Balkovec J., Vanmiddlesworth F. In vitro antifungal activities and in vivo efficacies of 1,3-beta-D-glucan synthesis inhibitors L-671,329, L-646,991, tetrahydroechinocandin B, and L-687,781, a papulacandin. Antimicrob Agents Chemother. 1992 Aug;36(8):1648–1657. doi: 10.1128/aac.36.8.1648. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bartizal K., Scott T., Abruzzo G. K., Gill C. J., Pacholok C., Lynch L., Kropp H. In vitro evaluation of the pneumocandin antifungal agent L-733560, a new water-soluble hybrid of L-705589 and L-731373. Antimicrob Agents Chemother. 1995 May;39(5):1070–1076. doi: 10.1128/aac.39.5.1070. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bouffard F. A., Zambias R. A., Dropinski J. F., Balkovec J. M., Hammond M. L., Abruzzo G. K., Bartizal K. F., Marrinan J. A., Kurtz M. B., McFadden D. C. Synthesis and antifungal activity of novel cationic pneumocandin B(o) derivatives. J Med Chem. 1994 Jan 21;37(2):222–225. doi: 10.1021/jm00028a003. [DOI] [PubMed] [Google Scholar]
- Denning D. W., Stevens D. A. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother. 1991 Jul;35(7):1329–1333. doi: 10.1128/aac.35.7.1329. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Liberator P. A., Anderson J. W., Powles M., Pittarelli L. A., Worley M., Becker-Hapak M., Graves D. C., Schmatz D. M. Comparative study of antipneumocystis agents in rats by using a Pneumocystis carinii-specific DNA probe to quantitate infection. J Clin Microbiol. 1992 Nov;30(11):2968–2974. doi: 10.1128/jcm.30.11.2968-2974.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nollstadt K. H., Powles M. A., Fujioka H., Aikawa M., Schmatz D. M. Use of beta-1,3-glucan-specific antibody to study the cyst wall of Pneumocystis carinii and effects of pneumocandin B0 analog L-733,560. Antimicrob Agents Chemother. 1994 Oct;38(10):2258–2265. doi: 10.1128/aac.38.10.2258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Powles M. A., McFadden D. C., Liberator P. A., Anderson J. W., Vadas E. B., Meisner D., Schmatz D. M. Aerosolized L-693,989 for Pneumocystis carinii prophylaxis in rats. Antimicrob Agents Chemother. 1994 Jun;38(6):1397–1401. doi: 10.1128/aac.38.6.1397. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schmatz D. M., Abruzzo G., Powles M. A., McFadden D. C., Balkovec J. M., Black R. M., Nollstadt K., Bartizal K. Pneumocandins from Zalerion arboricola. IV. Biological evaluation of natural and semisynthetic pneumocandins for activity against Pneumocystis carinii and Candida species. J Antibiot (Tokyo) 1992 Dec;45(12):1886–1891. doi: 10.7164/antibiotics.45.1886. [DOI] [PubMed] [Google Scholar]
- Schmatz D. M., Powles M. A., McFadden D. C., Pittarelli L., Balkovec J., Hammond M., Zambias R., Liberator P., Anderson J. Antipneumocystis activity of water-soluble lipopeptide L-693,989 in rats. Antimicrob Agents Chemother. 1992 Sep;36(9):1964–1970. doi: 10.1128/aac.36.9.1964. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schwartz R. E., Sesin D. F., Joshua H., Wilson K. E., Kempf A. J., Goklen K. A., Kuehner D., Gailliot P., Gleason C., White R. Pneumocandins from Zalerion arboricola. I. Discovery and isolation. J Antibiot (Tokyo) 1992 Dec;45(12):1853–1866. doi: 10.7164/antibiotics.45.1853. [DOI] [PubMed] [Google Scholar]
- Taft C. S., Stark T., Selitrennikoff C. P. Cilofungin (LY121019) inhibits Candida albicans (1-3)-beta-D-glucan synthase activity. Antimicrob Agents Chemother. 1988 Dec;32(12):1901–1903. doi: 10.1128/aac.32.12.1901. [DOI] [PMC free article] [PubMed] [Google Scholar]